Scientists Turn Tumor Bacteria Into a Cancer Drug: Meet aurB

Why we're writing about this one

Most of what lands in this column is semaglutide, tirzepatide, retatrutide: the GLP-1 world our readers already track closely, and the anti-aging peptides that follow it. aurB is neither. It's a peptide being developed against prostate cancer, built from a protein pulled out of bacteria that live inside tumors. It's not something you'll be able to buy, dose, or research on your own any time soon.

We're covering it anyway, briefly, because it's a genuinely new idea in peptide science that almost no one else has written about in plain language yet, and because it's a good example of how wide the word "peptide" actually stretches, beyond the compounds most of our readers are comparing prices on this week.

The idea: use the tumor's own bacteria against it

Researchers at the University of Illinois Chicago, led by Tohru Yamada, PhD (associate professor of surgery and biomedical engineering, and a member of the University of Illinois Cancer Center), started from an odd fact. Tumors have their own resident bacteria, living in what's called the tumor microenvironment. Scientists have increasingly looked at these bacteria as a source of anti-tumor compounds rather than just bystanders.

Yamada's lab had already built one cancer peptide this way, from a bacterial protein called a cupredoxin, a copper-containing protein that shuttles electrons between other proteins. That earlier peptide worked, including in human trials and in pediatric brain cancer, but it had a catch. Its effect depended on a working copy of p53, a tumor-suppressor gene that's mutated in a large share of cancers. When p53 is knocked out, as it is in many aggressive tumors, that peptide loses its edge.

So the team went looking for a second bacterial protein that could disable a tumor without needing p53's help. Sequencing bacteria pulled from breast cancer patients' tumor samples, they found one carrying a cupredoxin called auracyanin. They built a peptide drug modeled on it and named it aurB.

How aurB works: cutting off the fuel line

Molecular experiments showed aurB gets inside tumor cells' mitochondria, the structures that generate a cell's energy, and binds to ATP synthase, the enzyme responsible for producing ATP, the molecule cells run on. Block ATP synthase, and the cell's power plant stalls.

"The mitochondria are very important for a cell to survive; they are the energy factories," Yamada said. "Many cancer cells exhibit altered mitochondrial number and activity, because a cancer cell has to grow aggressively and rapidly. Therefore, the mitochondria would be an ideal target for cancer therapy."

Unlike the lab's earlier peptide, this mechanism doesn't route through p53, which means it's designed to work in p53-inactive tumors too, a category that includes many of the hardest-to-treat cancers.

Published, but still early: both things are true

It's worth being precise here, because it's easy to blur two different questions: has this been reviewed by other scientists, and has it been tested in people? The answers are different.

The research was published in Signal Transduction and Targeted Therapy, a peer-reviewed journal in the Nature portfolio, so this isn't a preprint or a press release standing alone. It went through peer review. What it has not been through is a human clinical trial. Every result described above comes from cell cultures and mouse models. Prostate cancer in a mouse is not prostate cancer in a person, and treatments that work well in animal models frequently fail, get modified, or take years to reach people, if they get there at all.

The UIC team has patented aurB through the university's Office of Technology Management and says they're now exploring paths toward human clinical trials. That's a meaningful next step, but it's a future one. There's no timeline yet, and no guarantee the peptide performs the same way in people as it did in mice.

The bigger pattern worth watching

Yamada's team frames aurB as a proof of concept more than an endpoint. Their view: auracyanin is probably just one of many bacterial proteins with drug potential still sitting undiscovered inside tumor microbiomes.

"There are many other bacterial proteins that could be source of cancer drugs," Yamada said. "We simply haven't tried them yet."

That's the part that makes aurB worth a mention here even though it has nothing to do with per-mg pricing or vendor vetting: it's a reminder that "peptide" as a category is much bigger than the GLP-1 and longevity compounds most of our readers track, and that some of the more interesting peptide science happening right now is aimed squarely at cancer, not weight or aging.